BioCryst Pharmaceuticals, Inc. (BCRX) Financial Statements (2023 and Earlier)

Company Profile

Business Address 4505 EMPEROR BOULEVARD
DURHAM, NC 27703
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance Sheet (Statement of Financial Position) ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments5083001361041145552
Cash and cash equivalents50427211427502229
Short-term investments3282278643323
Restricted cash and investments3222322
Receivables28224696
Inventory, net of allowances, customer advances and progress billings167 2 12
Inventory167 2 12
Deferred costs   0000
Other undisclosed current assets37642115
Total current assets:5663241641141256766
Noncurrent Assets
Property, plant and equipment977910105
Long-term investments and receivables7  2241948
Long-term investments7  2241948
Other noncurrent assets6441245
Other undisclosed noncurrent assets     00
Total noncurrent assets:22111132532359
TOTAL ASSETS:58833517514717890125
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities100745036312432
Accounts payable2819148649
Accrued liabilities73342116131116
Interest and dividends payable 2215121297
Deferred revenue102
Debt 314034352830
Deferred revenue and credits82 
Other undisclosed current liabilities2  0  2
Total current liabilities:1041069269755464
Noncurrent Liabilities
Long-term debt and lease obligation1421243    
Long-term debt, excluding current maturities136120     
Finance lease, liability 43
Operating lease, liability6  
Liabilities, other than long-term debt   00810
Deferred revenue and credits0810
Deferred rent credit   0
Total noncurrent liabilities:148124300810
Total liabilities:2522299670756374
Stockholders' equity
Stockholders' equity attributable to parent(107)(19)384984248
Common stock2221111
Additional paid in capital1,0981,002877780715567558
Accumulated other comprehensive income (loss)000(0)(0)(0)(0)
Accumulated deficit(1,208)(1,023)(841)(732)(632)(566)(511)
Total stockholders' equity:(107)(19)384984248
Other undisclosed liabilities and equity443125412820252
TOTAL LIABILITIES AND EQUITY:58833517514717890125

Income Statement (P&L) ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenues157184921252648
Revenue, net252648
Cost of revenue(7)(2)(4) (1)(2)(1)
Cost of goods and services sold(7)(2)(4) (1)(2)(1)
Gross profit:150164521242447
Operating expenses(328)(191)(145)(115)(81)(73)(86)
Operating loss:(178)(175)(99)(94)(57)(49)(39)
Interest and debt expense(3)(17)(12)(9)(9)(6)(5)
Other undisclosed income from continuing operations before equity method investments, income taxes 8     
Loss from continuing operations before equity method investments, income taxes:(181)(183)(111)(103)(66)(55)(45)
Other undisclosed loss from continuing operations before income taxes(1)      
Loss from continuing operations before income taxes:(182)(183)(111)(103)(66)(55)(45)
Income tax expense(2)      
Net loss:(184)(183)(111)(103)(66)(55)(45)
Other undisclosed net income (loss) attributable to parent  220(0)2
Net loss available to common stockholders, diluted:(184)(183)(109)(101)(66)(55)(43)

Comprehensive Income ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss:(184)(183)(111)(103)(66)(55)(45)
Other comprehensive income (loss)0(0)0(0)(0)0(0)
Comprehensive loss:(184)(183)(111)(103)(66)(55)(45)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent  220(0)2
Comprehensive loss, net of tax, attributable to parent:(184)(183)(109)(101)(66)(55)(43)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: